Back to Search
Start Over
Guillain-Barre syndrome in 220 patients with COVID-19.
- Source :
-
Egyptian Journal of Neurology, Psychiatry & Neurosurgery . 5/4/2021, Vol. 57 Issue 1, p1-7. 7p. - Publication Year :
- 2021
-
Abstract
- This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection. [ABSTRACT FROM AUTHOR]
- Subjects :
- *GUILLAIN-Barre syndrome
*COVID-19
*SARS-CoV-2
*AGE groups
*PANDEMICS
Subjects
Details
- Language :
- English
- ISSN :
- 11101083
- Volume :
- 57
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Egyptian Journal of Neurology, Psychiatry & Neurosurgery
- Publication Type :
- Academic Journal
- Accession number :
- 150149973
- Full Text :
- https://doi.org/10.1186/s41983-021-00310-7